JP2024028658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024028658A5 JP2024028658A5 JP2024010498A JP2024010498A JP2024028658A5 JP 2024028658 A5 JP2024028658 A5 JP 2024028658A5 JP 2024010498 A JP2024010498 A JP 2024010498A JP 2024010498 A JP2024010498 A JP 2024010498A JP 2024028658 A5 JP2024028658 A5 JP 2024028658A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- single nucleotide
- nucleotide polymorphisms
- group
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025060904A JP2025096332A (ja) | 2015-12-03 | 2025-04-02 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262589P | 2015-12-03 | 2015-12-03 | |
| US62/262,589 | 2015-12-03 | ||
| US201662291274P | 2016-02-04 | 2016-02-04 | |
| US62/291,274 | 2016-02-04 | ||
| JP2021043218A JP7233754B2 (ja) | 2015-12-03 | 2021-03-17 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
| JP2023021608A JP7429318B2 (ja) | 2015-12-03 | 2023-02-15 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023021608A Division JP7429318B2 (ja) | 2015-12-03 | 2023-02-15 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060904A Division JP2025096332A (ja) | 2015-12-03 | 2025-04-02 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024028658A JP2024028658A (ja) | 2024-03-04 |
| JP2024028658A5 true JP2024028658A5 (https=) | 2024-03-27 |
| JP7661545B2 JP7661545B2 (ja) | 2025-04-14 |
Family
ID=57758695
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528667A Active JP6855480B2 (ja) | 2015-12-03 | 2016-12-01 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
| JP2021043218A Active JP7233754B2 (ja) | 2015-12-03 | 2021-03-17 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
| JP2023021608A Active JP7429318B2 (ja) | 2015-12-03 | 2023-02-15 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
| JP2024010498A Active JP7661545B2 (ja) | 2015-12-03 | 2024-01-26 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
| JP2025060904A Pending JP2025096332A (ja) | 2015-12-03 | 2025-04-02 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528667A Active JP6855480B2 (ja) | 2015-12-03 | 2016-12-01 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
| JP2021043218A Active JP7233754B2 (ja) | 2015-12-03 | 2021-03-17 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
| JP2023021608A Active JP7429318B2 (ja) | 2015-12-03 | 2023-02-15 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060904A Pending JP2025096332A (ja) | 2015-12-03 | 2025-04-02 | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11769597B2 (https=) |
| EP (3) | EP4559524A3 (https=) |
| JP (5) | JP6855480B2 (https=) |
| KR (4) | KR102183910B1 (https=) |
| CN (2) | CN114712497B (https=) |
| AU (4) | AU2016364817B2 (https=) |
| CA (3) | CA3137326C (https=) |
| DK (1) | DK3384049T3 (https=) |
| ES (1) | ES2956007T3 (https=) |
| FI (1) | FI3384049T3 (https=) |
| HR (1) | HRP20231379T1 (https=) |
| HU (1) | HUE063335T2 (https=) |
| IL (4) | IL295808B2 (https=) |
| LT (1) | LT3384049T (https=) |
| MX (3) | MX2018006740A (https=) |
| NZ (1) | NZ744025A (https=) |
| PL (1) | PL3384049T3 (https=) |
| PT (1) | PT3384049T (https=) |
| RS (1) | RS64725B1 (https=) |
| SI (1) | SI3384049T1 (https=) |
| SM (1) | SMT202300314T1 (https=) |
| WO (1) | WO2017096031A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017096031A1 (en) * | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| GB201805642D0 (en) * | 2018-04-05 | 2018-05-23 | Macusoft Ltd | Determining a clinical outcome for a subject suffering from a macular degenerative disease |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| CN109632924B (zh) * | 2018-12-17 | 2022-02-08 | 上海市第一人民医院 | 人黄斑新生血管性疾病的血浆脂质标记物及其应用 |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR102625384B1 (ko) | 2020-09-28 | 2024-01-16 | (주) 플라즈닉스 | 플라즈마 토치 및 이를 이용하여 대상기체를 처리하는 방법 |
| JP7452892B2 (ja) * | 2022-06-20 | 2024-03-19 | 株式会社ニューギン | 遊技機 |
| JP7452889B2 (ja) * | 2022-06-20 | 2024-03-19 | 株式会社ニューギン | 遊技機 |
| JP7452891B2 (ja) * | 2022-06-20 | 2024-03-19 | 株式会社ニューギン | 遊技機 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03504499A (ja) | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
| DE4243524A1 (de) | 1992-12-22 | 1994-06-23 | Hoechst Ag | Gemische isomerer Nonanole und Decanole, ihre Herstellung, aus ihnen erhältliche Phthalsäureester und deren Verwendung als Weichmacher |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| DE19622283A1 (de) | 1996-05-23 | 1997-11-27 | Schering Ag | Verfahren zur terminalen Sterilisierung von befüllten Spritzen |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| DE19849922A1 (de) | 1998-10-29 | 2000-05-04 | Degussa | Verfahren zur Behandlung von Basen und organische Säuren enthaltenden wäßrigen Lösungen |
| DE19849924A1 (de) | 1998-10-29 | 2000-05-04 | Degussa | Verfahren zur Abtrennung organischer Säuren aus wäßrigen Lösungen |
| US6455743B1 (en) | 1998-11-27 | 2002-09-24 | Mitsubishi Chemical Corporation | Process for producing alcohols |
| DE19914259A1 (de) | 1999-03-29 | 2000-10-05 | Basf Ag | Verfahren zur destillativen Auftrennung eines flüssigen Rohaldehydgemisches |
| US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| DE19933348B4 (de) | 1999-07-16 | 2005-11-17 | Oxeno Olefinchemie Gmbh | Verfahren zur Reduzierung oxidischer Hydrierkontakte |
| US6777429B1 (en) | 1999-07-23 | 2004-08-17 | Novartis Ag | Ophthalmic composition |
| DE19957522A1 (de) | 1999-11-30 | 2001-05-31 | Oxeno Olefinchemie Gmbh | Verfahren zur katalytischen Durchführung von Aldolkondensationen mittels Mehrphasenreaktion |
| DE10103706A1 (de) | 2001-01-26 | 2002-08-14 | Aventis Behring Gmbh | Verwendung eines Hydrogenperoxid-Plasma-Sterilisationsverfahrens für die schonende Sterilisation temperaturempfindlicher Produkte |
| WO2003004098A1 (en) | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| JP2005511576A (ja) | 2001-11-09 | 2005-04-28 | アイテック・ファーマシューティカルズ | 眼球血管新生病を治療する方法 |
| JP4141156B2 (ja) | 2002-03-15 | 2008-08-27 | 日本ベクトン・ディッキンソン株式会社 | プランジャ後退制限機構付きプレフィルドシリンジ |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| CA2519835A1 (en) | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection |
| WO2004110490A2 (en) | 2003-06-06 | 2004-12-23 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
| WO2005016369A1 (en) | 2003-08-06 | 2005-02-24 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist in combination with radiation therapy |
| AU2005267741A1 (en) | 2004-07-30 | 2006-02-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| JP2008520242A (ja) | 2004-11-18 | 2008-06-19 | イェール ユニバーシティ | 視覚障害を処置するための方法および組成物 |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| CA2615636A1 (en) | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a vegf antagonist |
| EP1924309A1 (en) | 2005-09-16 | 2008-05-28 | (OSI) Eyetech Inc. | Ophthalmic syringe |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP1818069B1 (de) | 2006-02-14 | 2008-09-03 | Gerresheimer Bünde GmbH | Verfahren zum Herstellen von vorfüllbaren Spritzen |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US20100111963A1 (en) | 2006-11-10 | 2010-05-06 | Genentech, Inc. | Method for treating age-related macular degeneration |
| CN101600674B (zh) | 2006-11-30 | 2013-09-11 | 巴斯夫欧洲公司 | 烯烃的加氢甲酰化方法 |
| WO2008077155A1 (en) | 2006-12-21 | 2008-06-26 | Genentech, Inc. | Sterilization of objects containing biological molecules |
| US20100303813A1 (en) | 2007-06-08 | 2010-12-02 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| WO2009030976A1 (en) | 2007-09-03 | 2009-03-12 | Becton Dickinson France | Medical device and smooth coating therefor |
| AU2009323307B2 (en) | 2008-12-03 | 2015-02-19 | Denki Kagaku Kogyo Kabushiki Kaisha | Syringe |
| ES2600781T3 (es) * | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
| DE102009001594A1 (de) | 2009-03-17 | 2010-09-30 | Evonik Oxeno Gmbh | Verfahren zur Herstellung von alpha, beta-ungesättigten C10-Aldehyden |
| KR101191112B1 (ko) | 2009-03-19 | 2012-10-15 | 주식회사 엘지화학 | 고순도 2-에틸헥산올 생산을 위한 분리벽형 증류탑 및 이를 이용한 분별증류방법 |
| AR078060A1 (es) | 2009-07-14 | 2011-10-12 | Novartis Ag | Descontaminacion de superficie de contenedores previamente llenados en empaque secundario |
| DE102009045139A1 (de) | 2009-09-30 | 2011-03-31 | Evonik Oxeno Gmbh | Herstellung von alpha,beta-ungesättigten Aldehyden mittels einer Reaktionsmischpumpe |
| DE102009045718A1 (de) | 2009-10-15 | 2011-04-21 | Evonik Oxeno Gmbh | Verfahren zur Herstellung von Decanolen durch Hydrierung von Decenalen |
| MX2012004306A (es) | 2009-10-21 | 2012-04-30 | Genentech Inc | Polimorfismos geneticos en degeneracion macular relacionada con la edad. |
| CN102803189B (zh) | 2010-03-15 | 2016-01-20 | 埃克森美孚化学专利公司 | 用于生产醇的方法 |
| FR2966044B1 (fr) | 2010-10-18 | 2012-11-02 | Sanofi Pasteur | Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium |
| US8684190B2 (en) | 2010-11-19 | 2014-04-01 | Warren Abar | Multi-position solar panel rack |
| KR20190049934A (ko) | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| BR112013023724A2 (pt) * | 2011-03-15 | 2019-09-24 | Univ Utah Res Found | métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento |
| WO2013106765A1 (en) * | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
| DE202013000688U1 (de) | 2012-07-03 | 2013-03-05 | Novartis Ag | Glas-Spritze |
| KR20140042402A (ko) | 2012-09-28 | 2014-04-07 | 주식회사 엘지화학 | 올레핀으로부터 알코올의 제조장치 및 제조방법 |
| JP5721150B2 (ja) * | 2013-03-14 | 2015-05-20 | 学校法人 埼玉医科大学 | 加齢黄斑変性症の発症リスクの予測方法 |
| US9926246B2 (en) | 2013-05-03 | 2018-03-27 | Saudi Basic Industries Corporation | Integrated process for simultaneous production of oxo-alcohols and plasticizers |
| DK4374873T3 (da) | 2013-07-12 | 2025-11-03 | Astellas Us Llc | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande |
| JP6382816B2 (ja) | 2013-07-24 | 2018-08-29 | 田辺三菱製薬株式会社 | 眼科疾患治療剤 |
| DE102014201756A1 (de) | 2014-01-31 | 2015-08-06 | Evonik Degussa Gmbh | Reinigung chlorverschmutzter Organophosphorverbindungen |
| DE102014209536A1 (de) | 2014-05-20 | 2015-11-26 | Evonik Degussa Gmbh | Herstellung qualitativ hochwertiger Oxo-Alkohole aus unsteten Rohstoffquellen |
| EP3037400B1 (de) | 2014-12-23 | 2018-08-01 | Evonik Degussa GmbH | Chromfreie hydrierung von hydroformylierungsgemischen |
| EP3059005B1 (de) | 2015-02-18 | 2018-10-24 | Evonik Degussa GmbH | Abtrennung eines homogenkatalysators aus einem reaktionsgemisch mit hilfe organophiler nanofiltration unter besonderer berücksichtigung eines membran-leistungsindikators |
| SG10201601501QA (en) | 2015-03-05 | 2016-10-28 | Evonik Degussa Gmbh | Preparation of 2,2`-biaryls in the presence of molybdenum(v) chloride |
| CN104894261B (zh) * | 2015-06-02 | 2020-02-14 | 北京医院 | 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂盒 |
| PL3374366T3 (pl) | 2015-11-09 | 2020-05-18 | Evonik Operations Gmbh | Bis-fosforyny z jednostkami 2,4-dimetylofenylowymi i ich zastosowanie jako ligandów w hydroformylowaniu |
| EP3170805B1 (de) | 2015-11-19 | 2018-09-12 | Evonik Degussa GmbH | Beeinflussung der viskosität von auf n-buten basierenden estergemischen durch gezielten einsatz von ethen bei der herstellung der ester-vorprodukte |
| WO2017096031A1 (en) | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| ES2765635T3 (es) | 2016-05-19 | 2020-06-10 | Evonik Operations Gmbh | Producción de n-pentanal a partir de mezclas de sustancias de empleo pobres en buteno |
| US10245578B2 (en) | 2016-11-09 | 2019-04-02 | Evonik Degussa Gmbh | Chromium- and nickel-free hydrogenation of hydroformylation mixtures |
| DK3351526T3 (da) | 2017-01-20 | 2021-02-08 | Evonik Operations Gmbh | Diisopentylterephthalat |
| HUE059827T2 (hu) | 2017-11-30 | 2023-01-28 | Regeneron Pharma | VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére |
-
2016
- 2016-12-01 WO PCT/US2016/064403 patent/WO2017096031A1/en not_active Ceased
- 2016-12-01 DK DK16823372.4T patent/DK3384049T3/da active
- 2016-12-01 JP JP2018528667A patent/JP6855480B2/ja active Active
- 2016-12-01 IL IL295808A patent/IL295808B2/en unknown
- 2016-12-01 EP EP25169695.1A patent/EP4559524A3/en active Pending
- 2016-12-01 ES ES16823372T patent/ES2956007T3/es active Active
- 2016-12-01 NZ NZ744025A patent/NZ744025A/en unknown
- 2016-12-01 CA CA3137326A patent/CA3137326C/en active Active
- 2016-12-01 LT LTEPPCT/US2016/064403T patent/LT3384049T/lt unknown
- 2016-12-01 IL IL315458A patent/IL315458A/en unknown
- 2016-12-01 EP EP23180558.1A patent/EP4276199A3/en active Pending
- 2016-12-01 KR KR1020187017681A patent/KR102183910B1/ko active Active
- 2016-12-01 KR KR1020217041649A patent/KR20210157427A/ko not_active Ceased
- 2016-12-01 CA CA3007276A patent/CA3007276C/en active Active
- 2016-12-01 CA CA3179836A patent/CA3179836A1/en active Pending
- 2016-12-01 RS RS20230978A patent/RS64725B1/sr unknown
- 2016-12-01 PT PT168233724T patent/PT3384049T/pt unknown
- 2016-12-01 PL PL16823372.4T patent/PL3384049T3/pl unknown
- 2016-12-01 CN CN202210521088.6A patent/CN114712497B/zh active Active
- 2016-12-01 HU HUE16823372A patent/HUE063335T2/hu unknown
- 2016-12-01 AU AU2016364817A patent/AU2016364817B2/en active Active
- 2016-12-01 SM SM20230314T patent/SMT202300314T1/it unknown
- 2016-12-01 EP EP16823372.4A patent/EP3384049B1/en active Active
- 2016-12-01 CN CN201680070835.1A patent/CN108474039B/zh active Active
- 2016-12-01 KR KR1020207012363A patent/KR102261636B1/ko active Active
- 2016-12-01 FI FIEP16823372.4T patent/FI3384049T3/fi active
- 2016-12-01 MX MX2018006740A patent/MX2018006740A/es unknown
- 2016-12-01 KR KR1020217016566A patent/KR102343004B1/ko active Active
- 2016-12-01 SI SI201631732T patent/SI3384049T1/sl unknown
- 2016-12-01 IL IL302424A patent/IL302424B2/en unknown
- 2016-12-01 HR HRP20231379TT patent/HRP20231379T1/hr unknown
-
2018
- 2018-05-29 IL IL259672A patent/IL259672B2/en unknown
- 2018-06-01 MX MX2023008504A patent/MX2023008504A/es unknown
- 2018-06-01 MX MX2023004922A patent/MX2023004922A/es unknown
- 2018-06-01 US US15/995,518 patent/US11769597B2/en active Active
-
2020
- 2020-05-22 AU AU2020203362A patent/AU2020203362B2/en active Active
-
2021
- 2021-03-17 JP JP2021043218A patent/JP7233754B2/ja active Active
-
2022
- 2022-09-20 AU AU2022235529A patent/AU2022235529B2/en active Active
- 2022-09-20 AU AU2022235531A patent/AU2022235531B2/en active Active
-
2023
- 2023-02-15 JP JP2023021608A patent/JP7429318B2/ja active Active
- 2023-08-15 US US18/234,101 patent/US20240029897A1/en active Pending
-
2024
- 2024-01-26 JP JP2024010498A patent/JP7661545B2/ja active Active
-
2025
- 2025-04-02 JP JP2025060904A patent/JP2025096332A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024028658A5 (https=) | ||
| Singh-Bains et al. | Altered microglia and neurovasculature in the Alzheimer's disease cerebellum | |
| Khan et al. | Neuroglobin-overexpressing transgenic mice are resistant to cerebral and myocardial ischemia | |
| Higgs et al. | Thalassaemia | |
| Auburger et al. | 12q24 locus association with type 1 diabetes: SH2B3 or ATXN2? | |
| JP2022166039A5 (https=) | ||
| JP2014504857A5 (https=) | ||
| Wang et al. | Genetic influence on cigarette-induced cardiovascular disease | |
| Jane et al. | Understanding fetal globin gene expression: a step towards effective HbF reactivation in haemoglobinopathies. | |
| Han et al. | Fetal gene therapy of α-thalassemia in a mouse model | |
| WO2023220087A8 (en) | Oligonucleotide compositions and methods thereof | |
| Mizuno | More than 20 years of the discovery of Park2 | |
| Dzau et al. | Current perceptions of cardiovascular gene therapy | |
| Dove et al. | The adenomatous polyposis coli gene of the mouse in development and neoplasia | |
| Smulders et al. | Gene editing of wheat to reduce coeliac disease epitopes in gluten | |
| Stephen et al. | A comparative study of once daily versus twice daily tacrolimus in liver transplantation | |
| Suebsantiwongse | Ritual Sovereignty in Siam: Royal Sacraments and Brahmanical Liturgies in Ayutthaya and Rattanakosin | |
| Badria et al. | Metformin: a small molecule with multi-targets and diverse therapeutic applications | |
| USD27289S (en) | Design for a plate or analogous article | |
| Winrernttz et al. | Notes on Śrâddhas and Ancestral Worship among the Indo-European Nations | |
| JP2008505148A5 (https=) | ||
| Beers et al. | Expression of an Interstitial Lung Disease Associated Surfactant Protein C SFTPC) Mutation Produces Dynamic Alterations in the Alveolar Type 2 Epithelial Cell Transcriptome and a Fibrotic Lung Phenotype in Mice | |
| CN118547102A (zh) | 一种与薏苡种壳厚度显著关联的分子标记及其应用 | |
| JP2024528893A5 (https=) | ||
| Kolesnikov et al. | Comparative organization and the origin of noncoding regulatory RNA genes from X-chromosome inactivation center of human and mouse |